Far Infrared Radiation for Sickle Cell Pain Management
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00599482|
Recruitment Status : Unknown
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was: Active, not recruiting
First Posted : January 23, 2008
Last Update Posted : January 5, 2009
|Condition or disease||Intervention/treatment||Phase|
|Anemia, Sickle Cell||Radiation: Far Infrared Radiation (5μm to 20μm wavelength)||Phase 1|
Painful sickle cell crises are treated with hydration and analgesics. Ischemia is an absolute or relative shortage of the blood supply to an organ. Relative shortage means the mismatch of blood supply (oxygen delivery) and blood request for adequate oxygenation of tissue.
It is hereby postulated that far infrared radiation of the body will promote blood and oxygen supply to the affected tissues. In addition, the analgesic properties of far infrared will alleviate pain due to the crisis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||10 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Phase 1 Study to Examine the Use of Far Infrared Radiation for Pain Management During Sickle Cell Crisis|
|Study Start Date :||January 2008|
|Estimated Primary Completion Date :||September 2008|
|Estimated Study Completion Date :||January 2009|
Far Infrared Radiation
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far infrared radiation for 30 to 40 minutes during each session.
- Pain Management [ Time Frame: 40 minutes ]
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00599482
|The Centre for Incurable Diseases|
|Mississauga, Ontario, Canada, L5R 3G9|
|Study Chair:||Ken Nedd, M.D.||GAAD Medical Research Institute Inc.|
|Study Director:||Kwasi Donyina, Ph.D.||GAAD Medical Research Institute Inc.|